Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
A041702
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- NCT03737981 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on A041702 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on A041702 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib; Obinutuzumab; Observation Activity; Venetoclax
- Arms
- Arm I (ibrutinib, obinutuzumab) · Active comparator
- Arm II (ibrutinib, obinutuzumab, venetoclax) · Experimental
- Enrollment
- 465
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 31, 2019
- Primary completion
- Jan 17, 2025
- Results posted
- Yes
- Registry record
- NCT03737981 · updated Oct 26, 2026